Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

  • 5 mg - 194 EUR
  • 25 mg - 776 EUR
  • 100 mg - 2328 EUR


Bafetinib is an orally available, dual BCR/Abl and Lyn kinase inhibitor that was developed to treat BCR/Abl positive leukemias such as chronic myelogenous leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (AML). It is 25- to 55-fold more potent than imatinib in vitro and at least 10-fold more potent in vivo. Bafetinib inhibits 12 of the 13 most frequent imatinib-resistant Bcr-Abl isoforms originating from point mutations, but not that bearing the Thr315Ile mutation.

catalogue number: B096
synonyms: INNO-406, NS-187
CAS: 859212-16-1
MW: 576.62 g/mol

Blood. 2005 Dec 1;106(12):3948-54. PMID: 16105974
Curr Opin Investig Drugs. 2010 Dec;11(12):1450-65. PMID: 21154127

  • 5 mg - 74 EUR
  • 25 mg - 296 EUR
  • 100 mg - 888 EUR


Belinostat was found to inhibit in vitro cancer cell growth with sub- to low micromolar IC50 potency. It also exhibited synergistic activity when used in combination with certain chemotherapeutics and effectively inhibited the growth of multidrug-resistant cells. Belinostat is a hydroxamate-type inhibitor of histone deacetylase (HDAC) that inhibits HDAC activity in HeLa cell extracts with an IC50 of 27 nM and induces a concentration-dependent (0.2-5 microM) increase in acetylation of histone H4 in tumor cell lines.

catalogue number: B016
synonyms: PX105684,PXD101
CAS: 414864-00-9
MW: 318.35 g/mol

Mol Cancer Ther. 2003 Aug;2(8):721-8. PMID: 12939461
Mol Cancer Ther. 2006 Aug;5(8):2086-95. PMID: 16928830

  • 25 mg - 70 EUR
  • 100 mg - 210 EUR
  • 250 mg - 420 EUR


BEZ235 is an imidazo[4,5-c]quinoline derivative that competitively inhibits the PI3K and mTOR kinases, efficiently and selectively preventing dysfunctional activation of the PI3K pathway and thereby inducing G(1) arrest. It has an IC50 value of 4 nM against the p110a isoform of PI3K, 75 nM against the p110b isoform, 7 nM against the p110d isoform and 5 nM against the p110g isoform.

catalogue number: B017
synonyms: NVP-BEZ235
CAS: 915019-65-7
MW: 469.55 g/mol

Mol Cancer Ther. 2008 Jul;7(7):1851-63. PMID: 18606717
Cancer Res. 2008 Oct 1;68(19):8022-30. PMID: 18829560
Cancer Res. 2008 Nov 15;68(22):9221-30. PMID: 19010894

  • 5 mg - 97 EUR
  • 25 mg - 388 EUR
  • 100 mg - 1164 EUR

Bleomycin (sulfate)

Bleomycin is a glycopeptide antibiotic produced by Streptomyces verticillus and used in the treatment of Hodgkin lymphoma, squamous cell carcinomas, testicular cancer, pleurodesis and plantar warts. It is commonly thought to exert its biological effects as a metallodrug, which causes oxidative DNA damage. Bleomycin induces dioxygen activation and sequence-selective degradation of DNA and also mediates the oxidative degradation of all major classes of cellular RNA. The oxidation-reduction pathways involved in the reactions of iron-bleomycin, copper-bleomycin, and other metal-bleomycin species with O2 have been examined, and the complexes' photochemical activation has been studied.

catalogue number: B115
synonyms: Blenoxane
CAS: 9041-93-4
MW: 1512.62 g/mol (sulfate)

Chem Biol Interact. 1990;73(2-3):133-82. PMID: 1690086
J Nat Prod. 2000 Jan;63(1):158-68. PMID: 10650103

  • 5 mg - 41 EUR
  • 25 mg - 164 EUR
  • 100 mg - 492 EUR


The 2,6,9-trisubstituted purine derivative bohemine is a synthetic inhibitor of cyclin-dependent kinases that was developed from the original hit olomoucine. Bohemine inhibits CDK1 and CDK2 with IC50 values of around 1 microM. It also exhibits antitumour activity in vitro, with a mean IC50 value of 27 microM.

catalogue number: B018
CAS: 189232-42-6
MW: 340.43 g/mol

Electrophoresis. 2000 Nov;21(17):3757-64. PMID: 11271495
Technol Cancer Res Treat. 2002 Aug;1(4):247-56. PMID: 12625783
Clin Cancer Res. 2005 Jul 1;11(13):4875-87. PMID: 16000586

  • 5 mg - 103 EUR
  • 25 mg - 412 EUR
  • 100 mg - 1236 EUR


Bortezomib is a synthetic dipeptide boronic acid that acts a potent (Ki = 0.6 nM) and selective inhibitor of 26S proteasome activity. It has been approved as a drug for newly diagnosed multiple myeloma patients and for relapsed/refractory multiple myeloma and mantle cell lymphoma, for which it has become a treatment of choice.

catalogue number: B019
synonyms: Velcade, PS-341
CAS: 179324-69-7
MW: 384.24 g/mol

Clin Cancer Res. 1999 Sep;5(9):2638-45. PMID: 10499643
Curr Cancer Drug Targets. 2011 Mar;11(3):239-53. PMID: 21247388

  • 5 mg - 52 EUR
  • 25 mg - 208 EUR
  • 100 mg - 624 EUR


Bosutinib is a dual inhibitor of the SRC and ABL kinases. It inhibits the activating autophosphorylation of Bcr-Abl in CML cells and of v-Abl in fibroblasts. At concentrations that inhibit proliferation in CML cells, this inhibits the phosphorylation of cellular proteins such as STAT5. Preclinical studies demonstrated bosutinib to have strong antiproliferative activity in human and murine CML cell lines. It also performed well in clinical trials, exhibiting high clinical efficacy, good tolerability and low toxicity in imatinib-resistant or -intolerant CML patients.

catalogue number: B097
synonyms: SKI-606
CAS: 380843-75-4
MW: 530.45 g/mol

Cancer Res. 2003 Jan 15;63(2):375-81. PMID: 12543790
Expert Rev Hematol. 2009 Oct;2(5):489-97. PMID: 21083014
Crystal Structure of Human Serine Threonine Kinase- 10 Bound to Bosutinib PDB: 3ZZ2

  • 25 mg - 22 EUR
  • 100 mg - 65 EUR
  • 250 mg - 130 EUR


Busulfan is an alkyl sulfonate that functions as an alkylating antineoplastic agent. Its main clinical uses are in bone marrow transplantation, especially in chronic myelogenous leukemia. Because it is a bifunctional alkylating agent, it is likely to cause DNA damage, and this may be important in its cytotoxicity.

catalogue number: B116
synonyms: Myleran, Busulfex
CAS: 55-98-1
MW: 246.3 g/mol

Cancer Sci. 2004 May;95(5):454-8. PMID: 15132775